Detailed Information

Cited 5 time in webofscience Cited 7 time in scopus
Metadata Downloads

Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medicationsopen access

Authors
Zhang, Li TaoLee, Sung WonPark, KwangsungChung, Woo SikKim, Sae WoongHyun, Jae SeogMoon, Doo GeonYang, Sang-KukRyu, Ji KanYang, Dae YulMoon, Ki HakMin, Kweon SikPark, Jong Kwan
Issue Date
17-Jan-2014
Publisher
DOVE MEDICAL PRESS LTD
Keywords
alfuzosin; lower urinary tract symptoms; benign prostatic hyperplasia; antihypertensive medication; blood pressure
Citation
CLINICAL INTERVENTIONS IN AGING, v.10, pp 277 - 286
Pages
10
Indexed
SCIE
SCOPUS
Journal Title
CLINICAL INTERVENTIONS IN AGING
Volume
10
Start Page
277
End Page
286
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8583
DOI
10.2147/CIA.S74102
ISSN
1176-9092
1178-1998
Abstract
Background: The objective of this study was to assess the efficacy and safety of alfuzosin 10 mg monotherapy or combined antihypertensive medication on blood pressure (BP) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH/LUTS) with or without antihypertensive medication. Methods: This was a 3-month, multicenter, randomized, open-label study in 335 patients aged >45 years with a clinical diagnosis of BPH/LUTS by medical history and clinical examination, a total International Prostatic Symptom Score (IPSS) >= 8 points, a maximum flow rate >5 mL/sec and <= 15 mL/sec, and a voided volume >= 120 mL. Eligible subjects were randomized to receive alfuzosin 10 mg as monotherapy (group 1) or alfuzosin 10 mg + antihypertensive combination therapy (group 2). Based on baseline BP and hypertensive history with or without antihypertensive medications at first medical examination, group 1 was divided into two subgroups of normotensive and untreated hypertensive patients, and group 2 into two subgroups of controlled hypertensive and uncontrolled hypertensive patients. The primary study outcomes were change in IPSS, BP, and heart rate from baseline. Secondary outcomes were change in IPSS-quality of life score, maximum flow rate, average flow rate, voided volume, and post-voided volume. Results: The overall BP change was not significantly different between groups 1 and 2 (systolic BP, P=0.825; diastolic BP, P>0.999). In patients with uncontrolled or untreated hypertension, alfuzosin 10 mg alone or combined with antihypertensive therapy significantly decreased systolic and diastolic BP. The mean difference in total IPSS and IPSS-quality of life scores from baseline between groups 1 and 2 was 0.45 (95% CI: -1.26, 2.16) and 0.12 (95% CI: -0.21, 0.45), respectively (both P>0.05). Maximum flow rate, average flow rate, voided volume, and post-voided volume at endpoint were numerically, but not significantly, changed from baseline (all P>0.05). Conclusion: This study shows that alfuzosin 10 mg is effective and well tolerated in patients with BPH/LUTS with or without antihypertensive medications. However, in patients with uncontrolled or untreated hypertension, alfuzosin 10 mg alone or in combination with antihypertensive medication appears to decrease systolic and diastolic BP, and these patients should be warned about a decrease in BP on initiation of therapy.
Files in This Item
Appears in
Collections
2. Clinical Science > Department of Urology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Moon, Du Geon photo

Moon, Du Geon
Guro Hospital (Department of Urology, Guro Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE